Actinium Pharmaceuticals Faces Class Action Suit Over Alleged Securities Fraud Violations

Overview of the Lawsuit

Actinium Pharmaceuticals, Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company, has recently come under scrutiny due to alleged securities law violations. A class action lawsuit has been filed by Levi & Korsinsky LLP on behalf of the investors who may have suffered financial losses due to actions taken by the company from October 31, 2022, to August 2, 2024. This announcement was made on April 4, 2025, and representatives of the law firm urge affected shareholders to consider their legal options before the deadline on May 27, 2025.

Details of the Allegations

The lawsuit claims that several false statements were made and crucial information was concealed regarding the company's clinical trial data, particularly the Phase 3 Sierra trial results. The accusations include:

1. Misrepresentation of Data: It is alleged that the data from the Sierra trial would not meet the FDA's expectations for the approval of Actinium's targeted radiotherapy, Iomab-B BLA.
2. Unsubstantiated Claims: The investors were misled by the company's assertions about the additional analyses the FDA received, which were claimed to show improved Overall Survival. The legal team argues that these claims were misleading and insufficient for FDA approval.
3. Potential for Rejection: The complaint highlights that the FDA was likely to either reject the review of the Iomab-B Biologics License Application (BLA) outright or, should they choose to review it, they would find it unlikely to approve based on the data provided.
4. Misleading Information About Company Performance: Due to these issues, the lawsuit states that the positive statements made by the defendants regarding Actinium's operations and future prospects were materially misleading and lacked a reasonable basis.

Next Steps for Affected Investors

Investors who suffered losses during the relevant period are encouraged to act promptly, as the window to be appointed as a lead plaintiff in this class action is closing soon. Interested parties are advised that participation in the lawsuit does not incur any upfront costs, as class members may be entitled to compensation without any out-of-pocket expenses. This type of class action aims to hold the company accountable and secure financial redress for those affected.

Why Levi & Korsinsky?

Levi & Korsinsky LLP has a noteworthy reputation in securities litigation, having secured significant financial recoveries for shareholders over the past two decades. They emphasize their expertise in navigating complex legal matters and have a dedicated team of over 70 staff members dedicated to serving their clients. Their consistent recognition in the top echelons of securities litigation firms in the U.S. underlines their capability in managing challenging cases.

Conclusion

For Actinium Pharmaceuticals' investors, this lawsuit represents a significant opportunity to seek justice and potential financial recovery for losses endured during the alleged violations. Those concerned should act swiftly, as the deadline approaches. Contacting Levi & Korsinsky could provide important guidance on available legal options and the path forward toward compensation.

For more information, investors are encouraged to reach out via the provided contacts or visit their website for detailed guidance on how to participate in this class action lawsuit.